TARS Stock Analysis: Buy, Sell, or Hold?
TARS - Tarsus Pharmaceuticals, Inc. Common Stock
$72.08
-0.62 (-0.85%)
▼
5d:
+2.07%
30d:
+22.88%
90d:
+15.77%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When TARS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: TARS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: TARS shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$81.44
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$50.57
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TARS is currently trading at $72.08, which is considered extended relative to its 30-day fair value range of $58.31 to $69.73. From a valuation perspective, the stock is trading at a discount (Forward PE: 30.4) compared to its historical average (35.0). Remarkably, the market is currently pricing in an annual earnings decline of 4.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, TARS is showing sideways momentum. The price is approaching resistance at $73.51. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TARS scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $94.86 (+34.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TARS is showing sideways momentum. The price is approaching resistance at $73.51. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TARS scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $94.86 (+34.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$58.31 -
$69.73
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
42.3%
Protect Your Profits
Holding TARS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 34.3% below Wall St target ($94.86)
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$58.31 -
$69.73
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$5.40
(7.5%)
Support & Resistance Levels
Support Level
$62.85
Resistance Level
$73.51
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
30.37
Wall Street Target
$94.86
(+34.3%)
Revenue Growth (YoY)
69.4%
Profit Margin
-7.7%
Valuation Discount vs History
-4.6% cheaper
PE vs Historical
30.4 vs 35.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.6%
(market-implied from PE analysis)
1-Year Target
$67.37
(-5%)
2-Year Target
$64.27
(-9%)
3-Year Target
$61.31
(-13%)
3-Yr Target (if PE normalizes)
(PE: 30→35)
$70.65
(+0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 30.4 to 35.0
Stabilization Target:
$81.38
(+15.2%)
PE Expansion Potential:
+15.2%
Share & Embed Analysis
Last updated: August 24, 2026 10:46 AM ET
Data refreshes hourly during market hours. Next update: 11:46 AM
Data refreshes hourly during market hours. Next update: 11:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TARS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
16
Sells
Net
INSIDERS SELLING
Recent Transactions
Bryan Wahl
SELL
4231 shares
2026-03-19
Dianne C Whitfield
SELL
4174 shares
2026-03-19
Elizabeth Yeu Lin
SELL
390 shares
2026-03-19
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 33 SELL |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 34 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 55 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
Advanced TARS Option Strategies
Professional options setups generated by AI based on today's TARS price and gamma walls.
